Using Artificial Intelligence (AI) to enhance pharmacovigilance and side-effect reporting of new drugs
  The proposed PhD research will be conducted as part of the esteemed UK EPSRC funded COG-MHEAR research program, which aims to revolutionize the field of hearing assistive technology through the development of personalized multimodal solutions. This research project will focus on tackling crucial challenges in pharmacovigilance AI, specifically in evaluating online and social media forums to assess the impact of key drugs, both commonly used and new, on age-related hearing and cognitive impairment, including cognitive loss or listening effort.
The objective is to correlate the findings with existing harmacovigilance studies conducted by drug manufacturers, government organizations, and researchers. The insights gained from this research will significantly contribute to enhancing the context-aware personalized design of multimodal hearing aid prototypes currently under development within the COG-MHEAR program. By enabling the data-driven integration of historical and ongoing drug use, the PhD outcomes aim to empower COG-MHEAR AI prototype models to better predict and address the cognitive load experienced by hearing-aid users

  • Start Date:

    1 October 2024

  • End Date:

    30 September 2027

  • Activity Type:

    Externally Funded Research

  • Funder:

    Bawazeer group

  • Value:

    £36653

Project Team